ValuEngine upgraded shares of Insulet (NASDAQ:PODD) from a hold rating to a buy rating in a research report sent to investors on Monday.
PODD has been the topic of several other research reports. BidaskClub upgraded shares of Insulet from a buy rating to a strong-buy rating in a report on Friday, March 23rd. Oppenheimer set a $82.00 price objective on shares of Insulet and gave the stock a hold rating in a report on Thursday, February 22nd. Barclays restated a buy rating and set a $78.00 price objective on shares of Insulet in a report on Wednesday, December 13th. UBS upgraded shares of Insulet from a market perform rating to an outperform rating in a report on Monday, January 8th. Finally, Zacks Investment Research downgraded shares of Insulet from a hold rating to a sell rating in a report on Tuesday, January 9th. Seven analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and an average price target of $75.00.
Insulet stock opened at $86.08 on Monday. The company has a debt-to-equity ratio of 3.57, a quick ratio of 5.85 and a current ratio of 6.24. Insulet has a 12-month low of $38.43 and a 12-month high of $88.88. The firm has a market cap of $4,928.79, a P/E ratio of -187.13 and a beta of 1.38.
In related news, Director David A. Lemoine sold 641 shares of the stock in a transaction dated Tuesday, March 6th. The shares were sold at an average price of $76.81, for a total transaction of $49,235.21. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Shacey Petrovic sold 1,319 shares of the stock in a transaction dated Tuesday, March 6th. The shares were sold at an average price of $76.81, for a total transaction of $101,312.39. The disclosure for this sale can be found here. In the last quarter, insiders sold 28,800 shares of company stock valued at $2,412,739. 1.90% of the stock is currently owned by corporate insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of PODD. Cerebellum GP LLC bought a new position in Insulet during the fourth quarter valued at about $122,000. Equitec Specialists LLC bought a new position in Insulet during the fourth quarter valued at about $145,000. James Hambro & Partners bought a new position in Insulet during the fourth quarter valued at about $165,000. C M Bidwell & Associates Ltd. bought a new position in Insulet during the fourth quarter valued at about $188,000. Finally, Diversified Trust Co bought a new position in Insulet during the fourth quarter valued at about $218,000.
Insulet Company Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.